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Abstract
The increasing threat inherent to counterfeited drugs requires coordinated effort among
multiple actors with diverging interests. Although multiple initiatives exist, no
comprehensive and promising development and diffusion of a commonly applicable and
interoperable solution has taken place so far. Agreeing on standards is an essential step
on the road to a successful initiative on drug counterfeiting. To facilitate standardization,
especially the initiation of a standardization process, we propose the concept of Living
Labs as an innovative developing and testing environment serving multiple purposes.
Testing solutions in real-life-contexts, aligning multiple interests and resulting in a prestandard and a proof-of-concept are the advantages of this concept which facilitate the
participation and coordinated action among a broad set of different stakeholders.
Keywords: Collective Action, Living Labs, Standardization

1 Introduction
The infiltration of counterfeited pharmaceuticals into the pharmaceutical supply chain is
an increasing, international problem, in developing countries but also increasingly in
developed countries. The large volumes for pharmaceuticals, high margins for
counterfeited drugs and the low penalties in conjunction with low risk of detection
resemble an appealing field of activity for criminal minds.
Whereas a large number of anti-counterfeiting initiatives account for the
acknowledgement of the problem among industry members, governmental agencies, and
patient associations (OECD, 2007a), most of these initiatives focus on particular
solutions: Technology for enabling tracking and tracing, new packaging materials,
regulation for good manufacturing practices etc. The international cross-linking of the
pharmaceutical supply-chain, including multiple manufacturing phases across different
countries, cross-boundary trade of ingredients, semi-finished and packaged drugs,
emphasizes the need for a coordinated action among multiple stakeholders to face and
limit this problem sustainable. In light of this threat and the number of existing
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initiatives, the question can be raised, why no coordinated and transparency increasing
system has been established?
The example of developing and testing technical standards for this purpose is used in this
paper to propose a research design that may facilitate this kind of collective action among
multiple stakeholders.1 Interoperability with legacy systems of the stakeholders as well as
the integration into different regulative environments pose challenges for the prospective
technology enabled anticounterfeiting systems.
By drawing on standardization process models in the literature and identified
requirements we theorize that the concept of “Living Labs” can be used as an enabler of
collective action, establishing an environment among a group of core stakeholders to
identify and test pilot systems in real-life scenarios. Our argumentation is based on the
literature and experiences from current research projects in the pharmaceutical industry.
In the next section of this paper we will introduce the threat of counterfeited
pharmaceuticals as well as characteristics of current anti-counterfeiting initiatives to the
reader. Furthermore we motivate the need for standards as prerequisites for increasing
transparency in the supply chain. In the third section we propose to conceive standard
development as a threefold problem of collective action and Living Labs as a possible
enabler of Collective action. In the last section we will discuss whether a Living Lab can
serve as an incubator of collective action or not. This is followed by a brief conclusion.

2 Facing counterfeiting of pharmaceuticals
In this section we will introduce the reader to the increasing threat of counterfeited
drugs. A large number of initiatives on different national and international
levels, including governmental, intergovernmental, nongovernmental and private
stakeholders were established in the recent years. We will provide some propositions
about challenges faced by these initiatives that may explain the lack of observable
improvements in terms of secure pharmaceuticals.

2.1 Counterfeited drugs an increasing problem
Counterfeiting in general is an increasing problem concerning almost all consumer
goods. (OECD, 1998) In addition to the economic impact and the infringement of
intellectual property rights, counterfeit pharmaceuticals2 pose severe dangers for human
health or patient safety.
Potential counterfeits could harm the pharmaceutical supply-chain at multiple levels,
starting with the active ingredient over the finished pharmaceutical product and the
packaging. These levels also comprise the shipment and distribution activities. (OECD,
2007b) Figures according to the WHO state that 10% of the overall pharmaceuticals sold
were faked, ranging up 30% in the developing countries with a total volume of U$ 75
billion globally. (WHO, 2006-11-14)
1

In order to ensure the integrity of the whole supply chain we argue that a set of standards has to be
developed that may be used to set up a trackingtracing system (TTS) on an interorganizational level. In
this sense we conceive standards as multilateral agreements to ensure technical, organizational and
procedural interoperability and compatibility.
2
The Word Health Organization defines counterfeited pharmaceuticals as follows: “A product that is
deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can
apply to both branded and generic products and counterfeit medicines may include products with the
correct ingredients but fake packaging, with the wrong ingredients, without active ingredients or with
insufficient active ingredients.” WHO, 2006-11-14
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Several factors can be identified that facilitate the market entry of counterfeit medicines,
e.g. in Europe (Harper & Bertrand, 2006). As a result of the single EU market can
products that have illicitly entered one member state easily be disseminated throughout
the entire EU. In this regard the practice of parallel trade and re-import further aggravates
the complexity of the pharmaceutical supply chain. After being granted the authorization
by any EU national regulatory authority pharmaceutical distributors may import any drug
from any other member country to capitalize e.g. on substantial price differences among
different countries. Furthermore several member states (e.g. Germany, Netherlands,
Norway, Sweden, UK) stimulate dispensing of parallel imported pharmaceuticals in order
to reduce ever increasing healthcare costs (Kanavos et al., 2005). In UK the parallel
import accounted for 20 percent of total brand name prescription drug sales in 2002
(Kanavos et al., 2005).

2.2 Challenges for anti-counterfeiting initiatives
The primary goal of measures to tackle counterfeited pharmaceuticals is to ensure
integrity of the package, meaning for the patient to receive the unaltered medicine from
the manufactures. In this regard “securing the supply chain” means that at least the pointof-sale (pharmacy) can verify that the medicine or package is uncorrupted. This however
implies that both manufacturer and pharmacy have to collaborate and agree on
verification technologies and standards.
The different regulations have a strong impact on a coordinated effort of standardization
as well. The market for pharmaceuticals and their distribution is highly regulated
throughout the EU. While at the same time the free movement of goods is proclaimed
and legally enforced, slightly different legal frameworks can be observed in the EU.
These differences among particular regulations are also barriers for standardization
efforts, which should (especially) incorporate cross-boundary trade.
Lack of market incentives for the particular players might therefore impede coordinated
action amongst them. Neither the manufactures, nor wholesalers or pharmacies have a
strong incentive or position to enable a coordinated action, which affects even
international regulation.
Manufacturers for example might have an economic interest. But they might face the
dilemma of loss of reputation, when they prominently start action against the
counterfeiting threat (e.g. might the patients assume, that especially the drugs of this
manufacturer are counterfeited) having no solution at hand (because they just starting the
effort). Also other stages of the pharmaceutical supply chain (wholesale, retail) lack
either of power, economic incentives or both to implement more security in the supply
chain.
Governmental action can be assumed to overcome at least the lack of economic
incentives forcing the market actors to comply. Although protection of public health is
deemed to be a sovereign task such action is still missing. Various factors contribute to
this lack of governmental action. Rising mistrust by patients in politicians announcing the
requirement of a system (but at the same time having no system, not even a proof-ofconcept in sight) might impede here the government to tackle this issue prominently.
Missing detailed and industry specific knowledge, the challenge of aligning national and
international interests, and solving the problem of internationally distributed supply
chains might be additional reasons for the absence of governmental action.
In the previous paragraphs we have shown that neither the market nor the government
alone can provide the necessary standards and proof-of-concept to establish a viable
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solution. We conclude that a multi-stakeholder approach is needed to overcome the
individual rationalities that prevent the sufficient provision of the public good “patient
safety”.
A large number of initiatives on different national and international level, including
governmental, intergovernmental, non-governmental and private stakeholders (for a
detailed overview of initiatives see OECD, 2007a) have been established. They tackle a
broad range of issues, regarding technological, organizational and also regulatory issues.
Missing efforts to coordinate the single parts into common and comprehensive
approaches prevent them from being successful and sustainable for a broad set of
contexts.
The following table highlights potential shortcomings of existing initiatives or reasons of
failure from the perspective of the particular driving party:

Although most people in the pharmaceutical distribution industry acknowledge the
potential threat of counterfeited pharmaceuticals there is no industry-wide nor
international consensus that this relates to the own business or industry. As we have
shown the economic incentives will not lead industry-wide applicable solutions in the
near future. It has become clear that to overcome the threat of counterfeited
pharmaceuticals only a multi-stakeholder approach is feasible. Precedence in other
industries (e.g. beef) has shown that such approaches are gaining momentum after the
crisis broke out (e.g. BSE and CJD). Based on this unsatisfactorily observation the next
chapter introduces the theoretical grounding for our suggested research design which may
lead to feasible solutions before a crisis breaks out. Facing the problem of enabling a
standardization process, we illustrate the phases of standardization and the
required collective action. By presenting the concept of Living Labs and applying it in
our context we believe that it is possible to overcome or lower some of the barriers to
coordinated action presented previously.
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3 Theoretical Concepts
We want to conceive the formation of such a system as a problem of collective action
which would be needed for the development and consequent diffusion of a system. We
interpret this as a problem of standard development and distinguish several phases in
which actors have to assume different roles.

3.1 Phases of Standardization and Collective Action
In the previous sections we pointed out that standards are needed to ensure a close
cooperation between the actors along the supply chain and relevant governmental
agencies. By conforming to these standards the actors would be able to establish a
pharmaceutical security trade chain involving different stages of the supply chain from
different sectors and from different countries. The standards put forward here exhibit the
characteristics of collective goods (non-excludability, non-rivalry). Hence, Collective
Action Theory or Public Choice Theory seems a promising analytical viewpoint.
Markus et al. have studied the consequences that collective good characteristics have on
the development and diffusion process of standards. (Markus et al., 2006) By studying
vertical information system standards they explored the linkage and differences between
development and diffusion of standards as two distinct dilemmas. They come to the
conclusion that for a successful standardization both need to be solved and addressed at
the same time.
The development of a standard requires a close coordination of the actors. Farrell &
Saloner (1988) discuss three mechanisms to achieve coordination in regard to
compatibility standards. In this paper we want to focus on the first, which deals with
standardization committees in which negotiations take place before unilateral irrevocable
choices are made.
Before multilateral negotiations in such a context can take place the actors have to be
persuaded to join the consortium. Reimers and Li argue for a transaction cost perspective
to understand the individual firms‟ decision to join in (Reimers & Li, 2005). Following
their argument each firm has to evaluate the costs of multilateral negotiations in a
consortium and the costs it would incur by bilaterally negotiating with its business
partners. In this model the costs depend largely on the number of competitors and
intensity of competition among them. If several competing initiatives try to develop
standard candidates uncertainty increases. This in return increases transaction costs.
Therefore firms may prefer bilateral arrangements or simply adopt a free-rider position.
This leads to two problems: First, no initiative will take off because of the free-rider
problem. Second, the negotiating consortium might be too small to start a bandwagon
effect in the diffusion phase.
The dilemma of standard development is concerned with success and failure of a standard
negotiation process. By drawing on Reimers and Li we theorize that an explanation why
the negotiation process started at all is needed in the first place.
Following Reimers and Li we distinguish between three phases instandardization
processes (see Table 1): First, during the initiation phase the standard development
consortium is formed. A nucleus of actors or at least one actor has to take the role of the
initiative pusher by promoting or facilitating the formation of a forum to negotiate on
standards. The outcome is a relatively stable consortium of actors that are willing to
participate in the negotiation about a standard candidate. The standard is regarded as a
“candidate” as it may or may not emerge as a de-facto standard in the third phase. In
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Table 2 the phases of an abstract, consortium-driven standardization process and their
outcomes are listed.

Despite its importance the initiation phase is rather disregarded by the literature on
standardization. We therefore want to elaborate further on the challenges of the initiation
phase.
As already pointed out the initiation phase is concerned with actors assuming two roles:
the initiator and (passive) participants. One or more actors need to assume the role of an
initiator (irrespective of their number hereby called initiator).
During the initiation phase the initiator tries to identify and persuade the relevant actors
that need to participate in the consortium. The initiator may be motivated intrinsically
(e.g. economic incentives), by an exogenous event (e.g. a crisis) or it may be part of a
mission that has been entrusted to the initiator. In order to persuade actors to join the
consortium the initiator employs means that rely on resources at disposal of the initiator.
The persuasion of an actor has to be seen as a negotiation process in which the interests
between the actor and the initiator are aligned.
Alignment means that both parties need to agree on the rules that will govern the
consortium. Although they might have a diverging interest in the outcome of the
activities of the consortium they need to find a common ground where their expectations
are satisfied. In this regard the consortium needs to be interpretative flexible in order to
accommodate the diverging interests. At this stage the addressed actor needs to evaluate
the offer to participate in consortium. Despite a calculation of the (economic) costs and
benefits to participate or not in this consortium the actors will evaluate the initiator and
the other participants in terms of credibility, trustworthiness and past experiences.
During the standard development phase the decision making process exhibits several
potential areas of conflict between the parties. These are conflicts of interest, conflicts of
alignment and conflicts of appropriation. (Müller-Tengelmann, 1995) Conflicts of
interest refer to the heterogeneity of interests among the actors. For example some might
have preferred to develop a proprietary standard in order to lock-in their customers or
shut-out competitors. Another reason for supporting particular standard might be the
existing intra-organizational infrastructure (internal lock-in). This leads to the conflicts of
alignment. The conflicts of appropriation result from different cost/ benefit structures of
the actors. And even in case of a negative cost/benefit ratio, actors might still favor the
standard development.3

3

Müller-Tengelmann mentions three situations that would explain such behaviour. First there might be
dependencies among the actors that force some of them to be compliant to the requirements of their
(business) partner. Second the investment is justified by future expectations to sustain and strengthen
the business relationship. Alternatively costs can be passed on to a third party like customers or
suppliers (Müller-Tengelmann, 1995).
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After the standard candidate is developed the actors in the market have the choice to
adopt the standard (if it has not become a de-jure standard). Due to network effects actors
have the incentive to delay their adoption in order to wait until a critical mass has been
reached. Additionally dependencies and asymmetric power structures can also force or
impede actors to adopt a standard. Intellectual property rights at non-open standards,
missing practicability or incompleteness are further factors influencing the adoption and
diffusion process.
This section demonstrates that a standardization process is precarious and characterized
by a multiplicity of conflicts which have to be contained. The question arises how to setup an environment that provides promising surrounding conditions for a successful
initiation of a standardization process. We will elaborate on this question in the next
section by analyzing Living Labs as providing such an appropriate environment.

3.2 Living Labs an appropriate incubator for CA?
“Living Labs are collaborations of public-private partnerships in which stakeholders cocreate new products, services, businesses and technologies in real life environments and
virtual networks in multi-contextual spheres.”(Feuerstein et al., 2008)
This very broad definition of Living Labs is one indication for the typical characteristic
of this construct. There co-exist multiple, not necessarily mutual exclusive
understandings of what the concept “Living Lab” encompasses and how it could be
utilized in practice.4 For example, Mulder et al. (2008) emphasize the „Living‟ part of the
Living Lab. The integration and central meaning of the user in the research and design
process in a real life-context facilitates the inclusion of experiences and dynamics among
the technology, user and the social everyday context.
In addition to this conceptual work on Living Labs, empirical analyses of existing Living
Labs in Europe show some common characteristics among this type of collaboration
environment. They typically focus on the creation of innovative services featuring ICT
and involve stakeholders both from the public and private domain. (Shamsi, 2008) In
addition to governmental and commercial stakeholders, academia is another typical
stakeholder in the a Living Lab. (Almirall & Wareham, 2008)
Based on the definition by Feuerstein (2008) and Almirall (2008) and the empirical
findings from Shamsi (2008), we want to present our understanding of Living Labs in the
context of multi-national and multi-stakeholder research projects. In contrast to Mulder et
al. (2008), we focus not on the development of end-user technologies like ADSL or
mobile applications, but analyze the issue of establishing standardization activities
among a broad set of stakeholders with particular perspectives, interests and incentives.
Especially in the context of standards development, the preservation of stakeholders‟
interests is seen as one opportunity to involve and endure the collaboration of industry
members (David & Greenstein, 1990).

4

e.g. being it “a research methodology for sensing, prototyping, validating and refining complex
solutions in multiple and evolving real life contexts” [Prof. William Mitchell, MIT Boston; taken from
http://www.sricbi. com/LoD/meetings/2005-06-08/VPNiitamo.ppt] and similar usage in Souminen,
2005, “an experimentation environment in which technology is given shape in real life contexts and in
which (end) users are considered as ‚co-producers„“ Pierson, Lievens & Ballon, 2005, or a test
environment for different technologies and competing business models Niitamo, Kulkki & Hribernik,
2006.
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Therefore we propose the concept of Living Labs being a research environment, bringing
together a core group of stakeholders to explore potential solutions for a common
problem and with each party having particular perspectives and interests.
As mentioned before, one stakeholder, not necessarily involved in typical
Public-Private-Partnerships, is academia. Being an active part of a Living Lab, academia
can at least compensate some of the shortcomings inherent to initiatives driven mainly by
stakeholders from the public or private domain (as presented in Table 1). Being neutral
(in terms of economic interest) and unbiased (e.g. in terms of usage of a specific
technology) upfront and relying on scientific and theoretical knowledge, the credibility of
the university might be used to moderate and design a Living Lab.
The outcome is not only the presentation of a proof-of-concept, but also the formulation
of recommendations (in terms of legislation or organizational changes) and an
assessment of impact (e.g. in terms of economic impact) for the stakeholders of this reallife case. (Shamsi, 2008) Hence, the Living Lab could serve not only as a technological
testing environment, but also to evaluate future obstacles to a wider diffusion and
adoption. Based on the barriers to standardization and collective action activities and also
based on the very broad definition and current understanding of Living Labs presented in
the paragraphs before, we propose for our context four stages of designing and running a
Living Lab:
1. Funding and initiation
Related to a concrete or upcoming challenge, a governmental or
intergovernmental institution creates the opportunity to establish a Living Lab.
This first stage mainly aims to reduce the barriers (both financial and political
barriers) for the particular stakeholders to join this kind of research and
development projects.
2. Design and set-up
Due to the complexity of the problem, the concrete design and set-up of the
Living Lab could be done by an academic institution. Academia has multiple
advantages in contrast to political or commercial parties. It could be assumed, that
they are able to act neutrally, not being driven by financial or political interests
and therefore being creditable. Also their theoretical funding sustains their
credibility.
Typical tasks are defining and detailing the description of the problem,
considering potential technological solutions, establishing a network of
stakeholders (being it technology providers and users of the technology) and also
defining (in collaboration with the stakeholders) the outline of the following
phase.
3. Test, assessment, improvement
This phase has the most interrelations to the traditional innovation development
process. The specific setting of a Living Lab, focusing not on the development of
new technology, but the application, assessment and improvement of existing
technology (e.g. provided by particular partners) in real-life contexts, enables an
incorporation of multiple interests resulting in a proof-of-concept. Later diffusion
activities among regulatory bodies but also among a wider set of industry
stakeholders can be supported by conducting impact assessment.
4. Documentation and development of recommendation
Deriving recommendations on the basis of former results is the main task in the
last phase. The inclusion of scientific research, application to reallife- scenarios
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and the assessment by users into these recommendations should therefore provide
a basis for sustainable, well-proven and applicable solutions.
Figure 1 illustrates the phases with the particular results and also details the third phase,
which could encompass multiple test, assessment and improvement cycles.
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The alignment of particular interests and contributions among the network of
stakeholders has already been identified as being one important issue for enabling
standardization before. The following table therefore highlights the stakeholders of the
proposed Living Lab setting, each having particular interests and contributing
competencies.

Academia is one key actor in the Living Labs, with its neutral and scientific basis as
competencies. Combined with the mandate by the international institution, we believe
that the critical task of bringing together a key community and align its interest is one
central opportunity for the concept of Living Labs.

4 Use of a Living Lab approach to generate CA
Especially the first phase has been identified to be critical for establishing the momentum
for Collective Action. The following sections discuss the application of the Living Lab
concept in the initiation phase and the implications for the remaining two phases.

4.1 Phase I: Initiation
The standardization process via the coordination mechanism of a consortium requires
actors that bring together the participants of the consortium. This process previously
termed “initiation phase” is a necessary prerequisite to set a standardization process on
445
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track. As pointed out before this phase requires two roles which have to be assumed by
the actors. However even though an initiator might be motivated the actors may restrain
from joining the consortium and adopt a free-rider position. This seems to be likely in
case of dubious benefits but clear costs of participation. Furthermore the composition and
focus of the consortium may prevent actors from joining. In this regard the initiator (in
terms of a governmental/ intergovernmental institution) and also the designer (in terms of
academia) play a crucial role in convincing the respective actor of his neutrality and
mediating qualities which account for the ability to balance different interests and power
disequilibria among the participants.
In the case of anti-counterfeiting initiatives actors from all stages of the supply chain and
different legal frameworks have to be brought together. This results in a high degree of
heterogeneity among the actors. In such a consortium the multi-national, multi-billion
manufacturer has to collaborate with the pharmacist from the next door. Thus we have to
attribute this kind of consortium a high degree of heterogeneity not only in terms of
money or power but in their interests regarding the outcome as well.
A Living Lab as we introduced in the previous section has several characteristics that
may facilitate the initiation of a standardization process.
First of all a Living Lab is situated in the first phase of a standardization process and thus
has also implications for the latter stages. Typical Living Labs are funded by the EU.
This supranational governmental body provides financial funding for setting up Living
Labs. The objectives of this funding authority are to foster the competitiveness of
European research and industry. At the same time it expects recommendations for future
legislative acts and the political agenda. Universities or academic institutions are
competing on these funds by proposing projects. As projects are carried out under the
aegis of the proposing academic institution we will focus on their role as an initiator in
the standardization process. Despite being funded the academic institution
is interested in the research part in the Living Lab. By designing and settingup the
concrete Living Lab it assumes the role of an initiator. Several means are at its disposal
to persuade industry members to join the Living Lab. First and foremost, an academic
institution is commonly perceived as being a neutral actor that is neither politically nor
economically biased. This neutrality is especially helpful in case of power imbalances
among the future participants. Second, through the involvement of an academic
institution objective and scientifically grounded results are to be expected as an outcome.
The initiator of a Living Lab tries to bring technology providers, industrial users as well
as users from governmental institutions together. The incentives for each of these may be
different. The analysis and alignment of the particular interests is thus a critical task for
the neutral academic initiator. The technology provider expects to achieve a proof-ofconcept of his technology. Furthermore the LL may serve as a forum to raise attention for
a particular technology and discuss and test needed improvements in situ. The industrial
users can test the application of technology and cooperation mediated by technology with
partners (e.g. customs, other companies). As this is done in a controlled environment
with a limited scope it has only limited impact on regular business. In this regard it
represents a low-risk test environment (laboratory) but with results that are close to
reality (living).
The outcome of a Living Lab is a “pre-standard concept”. In most cases it cannot be
directly transformed into an actual de-jure standard nor can it be marketed as a de-facto
standard. This limitation is due to the limited scope in terms of involved stakeholders,
products and processes that have been analyzed. This analysis and the results of the
proof-of-concept are input for later phases of a standardization process. The major
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achievement however is to bring actors together in order to experiment on grand-scale
solutions in a comprehensive manner. Scale and comprehensiveness of such a proofofconcept are the major assets of Living Labs in contrast to market-driven initiatives.
Furthermore Living Labs are a vehicle to enable the actors to engage in technologies and
initiatives that may not provide direct economic benefits. Therefore they are a promising
means for governments to address the scarcity of public goods deemed beneficial for
society but which are not provided by the market.

4.2 Phase II-III: Development and Diffusion
Starting with a proof-of-concept, which has been tested in a real-life context and a prestandard, which already involves multiple requirements and interests should facilitate
phases II and III of the standardization process. The conflicts in the development phase
are often based on missing interests of single stakeholders. By already integrating
multiple stakeholders in the former phase and conducting impact assessment from
multiple perspectives, we assume that this potential threat can be lowered significantly.
In addition to the second phase, the proof-of-concept elaborated in the Living Lab can
also enable the diffusion among the network. The decision, if an innovative technology
or standard is adopted by one or respectively multiple parties relies, amongst other
factors, on the applicability and sustainability of the standard. In contrast to a standard
based on pure scientific and conceptual work, this standard has already proofed in a realcontext. In terms of network externalities, there exists already the core group of adopters
(the Living Lab community), which might serve as the required initial point or
„momentum‟ to facilitate the industry wide diffusion, e.g. by incorporating their
suppliers/customers etc.

4.3 Standardization and Drug Counterfeiting
The inherent challenges of drug counterfeiting discussed in chapter 2 illustrated the
complexity of the problem: Bringing multiple stakeholders together, facing a highly
explosive issue both for industry and politics, developing standards among different
stages of a highly branched supply chain, and incorporation of national and international
regulatory contexts. At the same time, it makes sense to tackle the issue before the
general necessity is discussed in the media, e.g. by creating a scandal as a consequence of
(more) serious incidents of counterfeited drugs. Overcoming the inherent barriers of these
challenges in the process of standardization using a Living Lab as a research environment
seems to be a promising solution:
From the technological perspective, multiple solutions like RFID, barcodes, tracking and
tracing systems etc. are available. Although they are often developed for different
contexts or tackling only very specific problems, Living Labs can be used to integrate
existing different solutions or apply them in new contexts. Also the test, application and
improvement in real-life context are important parts of a Living Lab with the aim to
present a proof-of-concept. Based on this proof-of-concept, recommendations for
regulation can be derived, but also concrete impact assessments can be conducted as
further steps of a successful introduction of standards.
From the organizational perspective, the multiplicity of stakeholders and the alignment of
interests might be an obstacle for successful standardization efforts. Although awareness
among public and private stakeholders exists, establishing an active collaboration often
requires further efforts. In this sense Living Labs could be used as a framework to lower
the financial and organizational barriers of collaboration. Being funded by a public
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institution and designed/organized by an academic institution the formation of
stakeholder group might be facilitated.
The third challenge for standardization activities regarding the problem of counterfeiting
is the potential discussion in the media and the loose of trust in the industry (esp. when
the problem is discussed but no solution or at least a potential solution is presented at the
same time). Living Labs could be used as some kind of real-life testing and developing
environment, but at the same time not being discussed that prominently in the media as
they are still limited to this (project) context.
By assessing the impact of solutions, not only from a financial but also from an
organizational perspective (e.g. in terms of social impact, strategic impact etc.) also the
diffusion of standards might be facilitated. Facing at least some of the challenges of drug
counterfeiting, we believe that concept of a Living Lab could facilitate the
standardization process significantly.

5 Conclusions
The counterfeiting of pharmaceuticals presents a rising problem for several stakeholders.
Ranging from being life-threatening for patients, over loss of trust against the medical
system up to huge economic risks, the potential threat for multiple stakeholders is
significant. Due to the nature of the problem, counterfeiting is not limited to a
geographical region, does not end at national boundaries or is limited to certain types of
pharmaceuticals. The complexity of the problem implies multiple challenges, e.g. how to
enable coordinated action among different stakeholders with different interests, acting in
different organizational and regulative environments etc. A number of initiatives are
already in place, but none of them incorporates a coordinated and supply-chain-wide
approach. The development of standards should therefore be the first step towards
increased transparency along the supply chain to face the counterfeiting problem.
Standardization processes can be distinguished in three phases: Initiation, development
and diffusion. Each of the phases contains particular challenges, which have to be
overcome to enable the whole process. By presenting the concept of Living Labs,
especially the conflicts of phase I (initiation) should be tackled in a structured way.
Academia as an economically and politically neutral actor could play the role of a
mediator between multiple stakeholders from different sectors to align their interests and
also ease the collaboration. Also phases II and III benefit from the concept of Living
Labs. As the typical result of a Living Lab is a proof-of-concept and first
recommendations for a pre-standard, the development of the real standard is supported.
Furthermore, the diffusion among the industry is facilitated: On the one hand, the
technology has already proven in real-life context and it also has been assessed. On this
basis the adoption decision among a wider community could be influenced. On the other
hand, the existing Living Lab community could serve as a nucleus for network/ industrywide diffusion.
The concept of Living Labs has been applied in multiple contexts, especially for driving
technological innovation. Actively enabling standardization activities is an innovative
application context and has therefore proven to work in real life. Future research in this
field can therefore be related to case studies of particular Living Labs. Further detailed
knowledge is needed concerning the concept of Living Labs entailing its roles and
phases.
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